Senseonics Holdings, Inc. (SENS) News
Filter SENS News Items
SENS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SENS News Highlights
- For SENS, its 30 day story count is now at 4.
- Over the past 24 days, the trend for SENS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SENS are MD.
Latest SENS News From Around the Web
Below are the latest news stories about SENSEONICS HOLDINGS INC that investors may wish to consider to help them evaluate SENS as an investment opportunity.
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with DiabetesGERMANTOWN, Md., June 02, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. |
Senseonics to Participate in the Jefferies Healthcare ConferenceGERMANTOWN, Md., May 26, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY. |
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue EstimatesSenseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Senseonics Holdings, Inc. Reports First Quarter 2023 Financial ResultsGERMANTOWN, Md., May 09, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2023. |
Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern TimeGERMANTOWN, Md., April 27, 2023--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023. |
The 3 Most Promising Healthcare Tech Stocks for April 2023The best healthcare tech stocks provide investors with impressive upside potential, while promising to improve the healthcare sector. |
ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOKAscensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense® E3 in the U.S. with a commercial update and outlook on future innovation, as discussed in the recent Eversense CGM Virtual Analyst and Investor Event. |
Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical TrialGERMANTOWN, Md., April 18, 2023--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes |
Senseonics Announces Equity Grants To Employees Under Inducement PlanGERMANTOWN, Md., April 05, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a). |
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial ResultsGERMANTOWN, Md., March 15, 2023--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022. |